TGFB1 and age-related macular degeneration: Most importantly, BAY651942 treatment also partially restored the expression of multiple AMD-associated risk factors that were altered during TGF–β/TNF–α-induced RPE–EMT, including complement factors, matrix metalloproteinases, solute carrier transport proteins, and pro-inflammatory cytokines.